Open Label Pilot Study of Perampanel for the Treatment of Alcohol Use Disorder

Summary

The purpose of this research study is to test the safety, tolerability, and effectiveness of the drug Perampanel when used in persons who drink and wish to stop drinking. Perampanel has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of seizures but has not yet been approved to treat alcohol use disorders. For this reason, it is considered an investigational drug. Some people in this study will receive Perampanel alone and some people will receive Perampanel and Disulfiram, this will be determined by the pharmacy.

Timeline

Start

2020-10-15

Primary completion

2021-08-11

Completion

2021-08-11

Drugs

Indications